Literature DB >> 32579991

The lung tissue microbiota features of 20 deceased patients with COVID-19.

Jun Fan1, Xiang Li1, Yong Gao2, Junjie Zhou1, Sihua Wang3, Bo Huang1, Junhua Wu1, Qin Cao1, Yajun Chen1, Zhenkao Wang1, Danju Luo1, Ting Zhou4, Ruiting Li4, You Shang4, Xiu Nie5.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32579991      PMCID: PMC7306202          DOI: 10.1016/j.jinf.2020.06.047

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


× No keyword cloud information.
To the Editor We read with great interest the article by Yanan Chu and colleagues, accepted for publication in the Journal of Infection. Secondary infection and sepsis are common complications in critically ill patients with COVID-19, , but the underlying pathogen is not clear. We investigated the microbiota characteristics of lung tissue from 20 deceased COVID-19 patients. All cases met the COVID-19 clinical diagnostic criteria provided by the National Health Commission of China, and died at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, between February 1, 2020, and March 31, 2020. The median age was 66 years (interquartile range, IQR, 60.75–77.0 years), 16 (80%) were older than 60 years and 14 (70.0%) were male. One patient had a history of exposure to the Huanan seafood market. On admission, most patients had fever (15 [75.0%]) and cough (15[75.0%]). Half of the patients had dyspnoea (10 [50.0%]) and fatigue or myalgia (10 [50.0%]). One-fifth of the patients had diarrhoea (4 [20%]). Other symptoms included chest pain, vomiting and headache. All 20 (100.0%) patients had findings of bilateral infiltrates on radiographic imaging. Fifteen (75.0%) patients had comorbidities, including cardiovascular disease (10 [50%]), hypertension (9 [45%]), malignancy (7 [35.0%]), diabetes (2 [10.0%]), chronic kidney disease (2 [10.0%]), and chronic lung disease (1 [5%]). The median time from symptom onset to hospital admission was 10 days (IQR, 6.75–14 days). The median time from hospital admission to death was 23 days (IQR, 20–30 days). Measures of vital signs were recorded on the day of hospital admission for all patients. The patients often developed tachypnoea, and the median respiratory rate was 25 (IQR, 20–30 breaths per minute). The patients had a median percutaneous oxygen saturation of 92% (IQR, 86.8%−97.3%)) on admission. The most common complications were respiratory failure (20 [100%]) and sepsis (18 [90%]), followed by liver dysfunction (17 [85%]), acute respiratory distress syndrome (14 [70%]), acute kidney injury (14 [70%]) and acute cardiac injury (14 [60%]). All patients received antibacterial therapy (20 [100%]) and antiviral therapy (20 [100%]). Most patients received glucocorticoid therapy (18 [90%]), and 12 patients received antifungal therapy (60%). In terms of ventilation modes, 4 patients (20%) received noninvasive ventilation, and invasive mechanical ventilation was required in 16 patients (80%). A total of 5 patients (25%) received continuous kidney replacement therapy (Table 1 ). In agreement with previous studies, our study confirmed that older men (>65 years) and those with comorbidities (especially malignancy) were more vulnerable to SARS-CoV-2 infection. Notably, sepsis was the most frequently observed complication. Immediately after death, postmortem needle core biopsies were performed on bilateral lungs in the negative-pressure isolation ward. The procedures were guided with ultrasound, and specimens were collected aseptically. Tissue cores were fixed in 10% neutral formalin immediately after being removed from the body, fixed for over 24 h, dehydrated in a graded series of ethanol, cleared in xylene, and then embedded in paraffin. A QIAamp DNA Mini Kit (QIAGEN, Hilden, Germany) was used to extract the total DNA from every FFPE tissue. The V3-V4 regions of the 16S rRNA samples were amplified by PCR, and the specific primers were 338F: 5-ACTCCTACGGGAGGCAGCA-3 and 806R: 5-GGACTACHVGGGT WTCTAAT-3. The ITS1 genes were amplified using barcoded ITS 5F: 5-GGAAGTAAAAGTCGTAACAAGG-3 and ITS1R: 5-GCTGCGTTCTTCATCGATGC-3. The quantified amplicons were pooled in equal amounts, and pair-end 2 × 300 bp sequencing was performed using the Illumina MiSeq platform with a MiSeq Reagent Kit v3. The sequencing data were analysed using QIIME V1.8.0 package. The bacterial distribution was characterized by the relative abundance of operational taxonomy units (OTUs). The most prevalent genera were Acinetobacter (80.70% of the total sequences), Chryseobacterium (2.68%), Burkholderia (2.00%), Brevundimonas (1.18%), Sphingobium (0.93%), and Enterobacteriaceae (0.68%), together comprising 92.32% of the total sequences and regularly detected in all subjects. Mycobacterium (3.59%) and Prevotella (0.56%) were detected mainly in patients 19 and 20(Fig. 1 A). The fungal community in the lung microbiome of each patient was analysed by ITS gene sequencing. The most common genus was Cutaneotrichosporon (Cryptococcus, 28.14%), followed by Issatchenkia (8.22%), Wallemia (4.77%), Cladosporium (4.67%), Alternaria (4.46%), Dipodascus (4.01%), Mortierella (3.22%), Aspergillus (2.72%), Naganishia (2.53%), Diutina (2.15%), and Candida (1.42%). Each patient's fungal infection status is shown in a heat map (Fig. 1B). More remarkably, the vast majority of patients had mixed bacterial and fungal infections.
Table 1

Demographic Characteristics of fatal Patients With COVID-19.

Characteristicsn = 20, n (%)
Median (IQR) age, years66 (60.75–77)
  <40 years1 (5)
  40–60 years3 (15)
  ≥60 years16 (80)
Sex
  Female6 (30)
  Male14 (70)
Huanan Seafood Market exposure1 (5)
Initial common symptoms
  Fever15 (75)
  Cough15 (75)
  dyspnea10 (50)
  Chest pain1 (5)
  Headache1 (5)
  Vomiting1 (5)
  Diarrhoea4 (20)
  Fatigue or myalgia10 (50)
Chest imaging, infiltratea
  Unilateral0 (0)
  Bilateral20 (100)
Comorbidities
  Hypertension9 (45)
  Diabetes2 (10)
  Cardiovascular disease10 (50)
  Chronic lung diseases1 (5)
  Chronic kidney disease2 (10)
  Malignancy7 (35)
Median (IQR) time from onset of symptom to hospital admission, days10 (6.75–14)
Median (IQR) time from hospital admission to death, days23 (20–30)
Vital signs on admission
Disorders of consciousness0 (0)
Median (IQR) arterial pressure, mm Hg137 (120–150)
Median (IQR) heart rate, beat per minute91 (79–103)
Median (IQR) respiratory rate, breaths per minute25 (20–30)
Median (IQR) percutaneous oxygen saturation,92% (86.8%−97.3%)
Complications
  Sepsis18 (90)
  Respiratory failure20 (100)
  Acute respiratory distress syndrome14 (70)
  Liver dysfunction17 (85)
  Acute kidney injury14 (70)
  Acute cardiac injury12 (60)
Treatment
  Antibacterial therapy20 (100)
  Antiviral therapy20 (100)
  Antifungal therapy12 (60)
  Glucocorticoids therapy18 (90)
  Intravenous immunoglobulin therapy11 (55)
  Interferon inhalation3 (15)
Oxygen treatment
  High flow nasal cannula1 (5)
  Noninvasive ventilation3 (15)
  Invasive mechanical ventilation16 (80)
  Continuous renal replacement therapy5 (25)
Extracorporeal membrane oxygenation0 (0)
Fig. 1

(A) Distribution of bacterial genera (OTUs) found in the lung samples of fatal COVID-19 patients defined by sequencing of the 16S rRNA gene. (B) Distribution of fungal genera (OTUs) found in the lung samples of fatal COVID-19 patients defined by sequencing of the ITS gene. Increasing depth of colour indicates the relative abundance of the OTU in an individual sample.

Demographic Characteristics of fatal Patients With COVID-19. (A) Distribution of bacterial genera (OTUs) found in the lung samples of fatal COVID-19 patients defined by sequencing of the 16S rRNA gene. (B) Distribution of fungal genera (OTUs) found in the lung samples of fatal COVID-19 patients defined by sequencing of the ITS gene. Increasing depth of colour indicates the relative abundance of the OTU in an individual sample. Although originally believed to be sterile, the lung exhibits a microbiota that varies in both physiological and pathological conditions. Many authors agree that healthy lung tissue has a low density of microbial populations, represented mainly by genera such as Prevotella, Veillonella, Streptococcus and Tropheryma. In our study, disorder of the lung microbiome was characterized by enrichment with the OTU of the Acinetobacter spp., which is usually comprised of Acinetobacter calcoaceticus, Acinetobacter baumannii, Acinetobacter nosocomialis, and Acinetobacter pittii, with Acinetobacter baumannii (AB) being the most clinically important species responsible for the highest incidence of multidrug resistance and mortality. It should be noted that Enterobacteriaceae spp., a kind of abundant taxonomic group in the human gut microbiome, was common in the lung tissues of fatal COVID-19 patients. The Enterobacteriaceae family of bacteria (a kind of taxon comprising many potentially pathogenic bacteria including Klebsiella, Escherichia coli, Proteus, Enterobacter, etc.) might release a large amount of endotoxin in the intestinal lumen, which would inhibit protein synthesis in intestinal epithelial cells. Significantly, we observed that the fungal communities in lung specimens were usually dominated by Cryptococcus spp. Cryptococcus infections have high morbidity and mortality rates worldwide, particularly in the context of immune suppression and central nervous system involvement. Moreover, we successfully detected Issatchenkia spp., Cladosporium spp., Cladosporium spp., Alternaria spp., Aspergillus spp., and Candida spp., all of which are important species for opportunistic invasive mycosis in immunocompromised patients. In general, persistent lymphocytic depletion, mechanical ventilation, corticosteroid therapy and prolonged hospital stays may lead to the development of opportunistic infections in fatal COVID-19. What is more important is that fatal COVID-19 is associated with complex mixed bacteria and fungal infections in the lungs. Therefore, it is urgent to serially monitor the microbiota in the lower respiratory tract for timely personalized treatment.

Declaration of Competing Interest

All authors declare no competing interests.
  35 in total

1.  Outcome of SARS-CoV-2 infection is linked to MAIT cell activation and cytotoxicity.

Authors:  Héloïse Flament; Matthieu Rouland; Lucie Beaudoin; Amine Toubal; Léo Bertrand; Samuel Lebourgeois; Camille Rousseau; Pauline Soulard; Zouriatou Gouda; Lucie Cagninacci; Antoine C Monteiro; Margarita Hurtado-Nedelec; Sandrine Luce; Karine Bailly; Muriel Andrieu; Benjamin Saintpierre; Franck Letourneur; Youenn Jouan; Mustapha Si-Tahar; Thomas Baranek; Christophe Paget; Christian Boitard; Anaïs Vallet-Pichard; Jean-François Gautier; Nadine Ajzenberg; Benjamin Terrier; Frédéric Pène; Jade Ghosn; Xavier Lescure; Yazdan Yazdanpanah; Benoit Visseaux; Diane Descamps; Jean-François Timsit; Renato C Monteiro; Agnès Lehuen
Journal:  Nat Immunol       Date:  2021-02-02       Impact factor: 25.606

Review 2.  Role of the Microbiome in the Pathogenesis of COVID-19.

Authors:  Rituparna De; Shanta Dutta
Journal:  Front Cell Infect Microbiol       Date:  2022-03-31       Impact factor: 5.293

Review 3.  Hallmarks of Severe COVID-19 Pathogenesis: A Pas de Deux Between Viral and Host Factors.

Authors:  Roberta Rovito; Matteo Augello; Assaf Ben-Haim; Valeria Bono; Antonella d'Arminio Monforte; Giulia Marchetti
Journal:  Front Immunol       Date:  2022-06-10       Impact factor: 8.786

4.  Endotracheal tube microbiome in hospitalized patients defined largely by hospital environment.

Authors:  Erika Alejandra Cifuentes; Maria A Sierra; Andrés Felipe Yepes; Ana Margarita Baldión; José Antonio Rojas; Carlos Arturo Álvarez-Moreno; Juan Manuel Anzola; María Mercedes Zambrano; Monica G Huertas
Journal:  Respir Res       Date:  2022-06-24

Review 5.  Microbiota in health and diseases.

Authors:  Kaijian Hou; Zhuo-Xun Wu; Xuan-Yu Chen; Jing-Quan Wang; Dongya Zhang; Chuanxing Xiao; Dan Zhu; Jagadish B Koya; Liuya Wei; Jilin Li; Zhe-Sheng Chen
Journal:  Signal Transduct Target Ther       Date:  2022-04-23

6.  The lower respiratory tract microbiome of critically ill patients with COVID-19.

Authors:  Paolo Gaibani; Elisa Viciani; Michele Bartoletti; Russell E Lewis; Tommaso Tonetti; Donatella Lombardo; Andrea Castagnetti; Federica Bovo; Clara Solera Horna; Marco Ranieri; Pierluigi Viale; Maria Carla Re; Simone Ambretti
Journal:  Sci Rep       Date:  2021-05-12       Impact factor: 4.379

7.  The human microbiome and COVID-19: A systematic review.

Authors:  Shinya Yamamoto; Makoto Saito; Azumi Tamura; Diki Prawisuda; Taketoshi Mizutani; Hiroshi Yotsuyanagi
Journal:  PLoS One       Date:  2021-06-23       Impact factor: 3.752

Review 8.  The Young Age and Plant-Based Diet Hypothesis for Low SARS-CoV-2 Infection and COVID-19 Pandemic in Sub-Saharan Africa.

Authors:  Jack N Losso; MerryJean N Losso; Marco Toc; Joseph N Inungu; John W Finley
Journal:  Plant Foods Hum Nutr       Date:  2021-06-24       Impact factor: 3.921

9.  Obesity and diabetes as comorbidities for COVID-19: Underlying mechanisms and the role of viral-bacterial interactions.

Authors:  Ilja L Kruglikov; Manasi Shah; Philipp E Scherer
Journal:  Elife       Date:  2020-09-15       Impact factor: 8.140

Review 10.  Different aspects of frailty and COVID-19: points to consider in the current pandemic and future ones.

Authors:  Hani Hussien; Andra Nastasa; Mugurel Apetrii; Ionut Nistor; Mirko Petrovic; Adrian Covic
Journal:  BMC Geriatr       Date:  2021-06-27       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.